Find Clinical Trials

Inclusion Criteria: * Pregnant women aged 15-49 years. * Gestational age between 16 and 20 weeks at enrolment. * Diagnosed with both gestational diabetes mellitus (GDM) and pregnancy-induced hypertension (PIH). * At least one prior antenatal visit at the study site. Exclusion Criteria: * Pre-existing diabetes mellitus or chronic hypertension prior to pregnancy. * Pre-existing renal disease, thyroid disease, or major hematological disorders. * Multiple pregnancy (e.g., twins, triplets). * Severe psychiatric illness.

Inclusion Criteria: * patient of the participating health center clinic * age 20 years and older * positive screen for food insecurity using a validated two-question tool * physician diagnosed HTN and continued indications of SBP \>130 mmHG Exclusion Criteria: * prior history of cardiovascular disease * unable to provide informed consent and complete study procedures in English

Inclusion Criteria: * Clinically diagnosed Type 2 Diabetes Mellitus * Aged 40 to 65 years * Not treated with insulin * Stable diabetes medication regimen for at least 3 months * Able to understand the study information and provide informed consent * Able to safely perform light-to-moderate cycling exercise Exclusion Criteria: * Current or recent use of insulin * Use of organic nitrates (e.g., glyceryl trinitrate) or phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) * Use of systemic antibiotics within the specified preparation period or regular use of antiseptic/antibacterial mouthwash during study participation * Use of supplements known to interfere with nitric oxide metabolism within the defined preparation period * Unstable or clinically significant cardiovascular disease * Uncontrolled hypertension or any condition that makes exercise unsafe * Chronic kidney disease, history of kidney stones, or other relevant renal conditions * Neurological, musculoskeletal or systemic disorders that impair safe participation * Known or suspected allergy or intolerance to beetroot, lemon or any component of the study products * Pregnancy or breastfeeding * Inability to comply with study preparation requirements

Inclusion Criteria: * Female (assigned at birth), ≥18 years old, and able to provide informed consent * Histologically confirmed metastatic or locally advanced breast cancer * Postmenopausal status defined by surgical or natural menopause, or ovarian suppression with a GnRH agonist * Prior treatment including at least one endocrine therapy in the metastatic setting, at least one CDK4/6 inhibitor (in the adjuvant and/or metastatic setting), and no more than two prior cytotoxic regimens in the metastatic setting * Radiologic disease progression on the most recent therapy * Measurable disease per RECIST v1.1 * Willingness to provide baseline and on-treatment tumor biopsies, unless not feasible or medically appropriate * ER-positive and HER2-negative status documented within 2 years * ECOG performance status 0-1 and life expectancy of at least 3 months * Adequate organ function Recovery from prior therapy-related toxicities to Grade ≤1 (except alopecia; neuropathy and endocrinopathies ≤Grade 2) * Ability to swallow oral medication and comply with study procedures * Stable dose (≥30 days) of bisphosphonates or denosumab, if applicable Exclusion Criteria: * Inflammatory breast cancer or known brain metastases * Recent major bleeding or uncontrolled bleeding disorder * Ongoing corticosteroid use \>10 mg/day (prednisone equivalent) * Recent anticancer or investigational therapy within 14 days (28 days for fulvestrant) * Untreated or unstable spinal cord compression * Significant cardiovascular disease within 6 months or ongoing uncontrolled cardiac conditions * Active or uncontrolled infection (controlled HIV or treated hepatitis C allowed) * Uncontrolled renal, pancreatic, or liver disease (excluding stable conditions such as Gilbert's syndrome or liver metastases) * Another malignancy requiring treatment within 2 years (except low-risk, curatively treated cancers) * Major surgery within 28 days * Any condition that may interfere with safety or study compliance * Pregnancy or breastfeeding

Inclusion Criteria: 1. Adults aged 18 years or over. 2. Diagnosis bipolar disorder in a current depressive episode based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria assessed by structured clinical assessment, Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al.,1998). 3. Having at least a moderate severity of depressive symptoms as measured by a score of at least 18 in MADRS (Montgomery and Åsberg, 1979). 4. Either not taking antidepressant medication or taking a stable dose of antidepressant medication for at least 6 weeks before enrolment. 5. Either not currently in psychotherapy or in ongoing psychotherapy for at least 6 weeks before enrolment. 6. Being under care of GP. 7. Agreeable for GP to be regularly informed by research team about participation. 8. Able to provide written, informed consent. Exclusion Criteria: 1. Significant suicide risk as measured by answering 'yes' to questions 4, 5 or 6 on the Columbia Suicide Severity Rating Scale (C-SSRS) Screen (Posner et al., 2011). 2. Primary comorbid psychiatric disorder (e.g. obsessive compulsive disorder) based on DSM criteria as assessed in MINI (Sheehan et al., 1998). 3. Having a Young Mania Rating Scale (Young et al., 1978) score of 20 or more. 4. Current daily use of medications that affect cortical excitability (e.g. benzodiazepines). 5. Current illicit drug use or heavy alcohol use with high risk of alcohol use disorder as measured by a score of \> 8 in Alcohol use disorders identification test consumption (AUDITC) (Khadlesari et al., 2017; NICE, 2023). 6. History of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), other brain stimulation, or psychosurgery for depression. 7. History of esketamine / ketamine for treatment of depression. 8. Medical disorder that may mimic mood disorder (e.g. hormonal disorder). 9. History of myocardial infarction, coronary artery bypass graft (CABG), coronary heart failure (CHF), or history of other cardiac issues. 10. Have cognitive impairment (e.g. dementia). 11. History of a neurological disorder (e.g., cerebrovascular events, stroke, structural lesion, epilepsy, seizures, Parkinson's disease). 12. History of migraines or intractable headaches. 13. Implant in brain, neurocranial defect or active implantable medical device. 14. Shrapnel or any ferromagnetic material in head. 15. If female and of child-bearing potential, currently pregnant or planning to become pregnant during the study 16. Concurrent enrolment in another interventional study.

Inclusion Criteria: 1. Food Insecurity Risk 2. Hypertension AND diabetes or obesity 3. Hospitalization, ED visit, OR outpatient visit in the past 12-months 4. NC resident 5. Valid email address Exclusion Criteria: * Living in a nursing home or residential facility where meals are prepared

Inclusion Criteria: * Aged greater than equal to (≥) 40 and less than (\<) 70 years * Male or female * Newly diagnosed with T2DM and initiated on anti-hyperglycemic treatment between 1 January 2022 and 31 December 2023 Exclusion Criteria: * If any exclusion criterion is met, the participant will be excluded from the study. * T1DM or gestational diabetes * Prescribed with any anti-hyperglycemic medications before first diagnosis of T2DM * Pregnant women * With pre-existing atherosclerotic CVD including coronary heart disease, stroke, transient ischemic attack, or peripheral artery disease * Died within 12 months after first diagnosis of T2DM * Lost to follow-up i.e., no visit 12 months (± 3 months) after first diagnosis of T2DM

Inclusion Criteria : * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * BMI≥ 35.0 kg/m\^2. * Participants without T2D: No history of T2D and HbA1c \< 6.5% (48 millimoles per mole (mmol/mol)) Participants with T2D: A history of T2D and HbA1c \< 10% (\< 86 mmol/mol). If a participant without a history of diabetes during the screening period receives an HbA1c result of 6.5% (48 mmol/mol) or higher, the investigator or the participant's healthcare provider must confirm the diagnosis of type 2 diabetes before the participant is randomised. Exclusion Criteria: * A self-reported change in body weight \> 5% within 90 days before screening, irrespective of medical records. * Use of any glucagon-like-peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin analogues, including medication with amylin activity, within 6 months before screening.

Inclusion Criteria: 1. Age at time of consent 18-75 years (inclusive) 2. Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least 6 months at time of screening 3. On insulin therapy for at least 3 months at time of screening, with no change to insulin regimen for 6 weeks prior (AID use within past 3 months excluded) to initiating baseline CGM data collection. * Regimen is defined as (1) Basal-bolus insulin therapy (a) using multiple daily injections of insulin (MDI), (b) non-automated insulin pump, or (c) MDI with premix insulin; or (2) basal insulin only (without bolus insulin). * Basal-bolus insulin therapy defined as use of a basal insulin (either long-acting or intermediate-acting (e.g., NPH) plus at least one mealtime insulin dose per day, or a non-automated insulin pump * Inhaled insulin may be used in addition to or instead of mealtime injections pre-study and as part of the Control group 4. For basal only users, screening A1C ≥7.5% and \<14.0%. For basal bolus users (i.e., all others), screening A1C ≥6.0% and \<14.0%. • A1C measurement within 28 days prior to enrollment is acceptable 5. Willing to use only the following types of U-100 insulin while using the study pump: Humalog, Novolog, Admelog, Kirsty, Fiasp, Lyumjev or their generic/biosimilar equivalents 6. Willing to use only study-provided Libre 2 Plus or 3 Plus sensor during the study and not use another sensor 7. Deemed appropriate for pump therapy per Investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities 8. No anticipated need to newly initiate noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that have a glucose lowering effect during the 26-week RCT phase. (Additions or changes in these medications will be permitted during the Extension Phase) 9. If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that have a glucose-lowering effect, prescribed dose has been stable for 6 weeks prior to baseline CGM collection; and there is not an anticipated need to increase the dose during the 26-week trial phase (dose reductions will be permitted for safety). 10. Investigator has confidence that the participant can safely operate all study devices and can adhere to the protocol 11. Willing to wear the system, including Pods, continuously throughout the 26-week trial phase 12. Willing and able to sign the Informed Consent Form (ICF) 13. Able to read and understand English 14. If of childbearing potential, willing and able to have pregnancy testing Exclusion Criteria: 1. Use of an automated insulin delivery pump within 3 months prior to screening 2. Any medical condition, which in the opinion of the Investigator, would put the participant at an unacceptable safety risk. This may include untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, unstable proliferative retinopathy, unstable psychiatric conditions such as eating disorders, drug or alcohol abuse. 3. Current or known history of coronary artery disease that is not stable with medical management in the opinion of the investigator, including unstable angina, despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening 4. Any planned surgery during the study which could be considered major in the opinion of the Investigator 5. History of more than 1 episode of severe hypoglycemia in the past 6 months. Severe hypoglycemia is defined as an event that requires the assistance of another person due to altered consciousness, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions. 6. History of more than 1 episode of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) in the past 6 months, unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis 7. Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement 8. Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of HbA1c 9. Plans to receive blood transfusion over the course of the 26-week trial phase. 10. Pregnant or lactating, or is of childbearing potential and not using an acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal). 11. Has taken systemic corticosteroids (oral or injectable) within 4 weeks or has had a local steroid injection (intraarticular, epidural) within 1 week prior to baseline CGM collection or plans to take oral or injectable steroids during the 26-week trial phase. 12. Participation in another clinical study using an investigational drug or device within prior 30 days or intends to participate in any other interventional study during the 26-week trial phase 13. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment 14. Participant is an employee of Insulet, an Investigator or a member of Investigator's study team, or immediate family member of any of the aforementioned

1. Inclusion criteria: 1. Patients with pathologically proven breast cancer 2. Metastatic breast cancer proved by pathology or radiological modalities. 3. Interval between 18F-FDG PET/CT and CE-CT from one to three weeks. 2. Exclusion criteria: 1. Patients with known concomitant malignancy 2. Patients receive systemic treatment chemotherapy or radiotherapy between 18F-FDG PET/CT and CE-CT.

Inclusion Criteria: According to local regulations, the subjects included in the study should meet the following criteria: 1. Male or female patients aged 18 years or above 2. Diagnosed with overweight or obesity, with a BMI of ≥ 24 kg/m² 3. Willing and able to use weight management apps 4. Willing and able to provide a written informed consent for participating in the study 5. Patients who meet the instructions for weight loss medication and have no contraindications to non-pharmacological treatments - Exclusion Criteria: 1. Having life-threatening comorbidities, with an expected lifespan of less than one year. 2. Participating in an interventional trial that requires informed consent. 3. Engaging in other organized weight loss programs or other clinical trials. 4. Researchers identify any situation that may endanger the safety or compliance of the subjects. \-

Inclusion Criteria: 1. aged between 13 to 24 years; 2. having mild to moderate depression and/or anxiety as assessed using a standardized assessment tool, i.e. Chinese Depression Anxiety Stress Scale-Youth (DASS-Y) with a DASS-Y Depression score between 5 and 12; 3. service users of The Salvation Army social service unit; and 4. giving informed consent to this research work. For those aged below 18, parental consent will be obtained. Exclusion Criteria: Those with severe depression (i.e. a DASS-Y Depression score ≥ 13) and/or severe anxiety (i.e. a DASS-Y Anxiety score ≥ 8) are excluded from this study.

Inclusion Criteria: 1. Chinese nationals 18 years old and above 2. No mental health treatment in the past 6 months 3. The patient diagnosis should meet one of the following ICD-10 diagnostic codes (or diagnosed as depressive state/anxiety state/anxious depression state): 1. Depressive disorder (F30-F39) 2. Fear anxiety disorder (F40) 3. Other anxiety disorders (F41) 4. Adjustment disorder (F43.2) 5. Organic/secondary related disorders (F06) 6. F1x.4 Depressive disorder caused by psychoactive substances (x is a substance category, e.g., F10.4 alcohol, F11.4 opioids, etc.) 7. F1x.0 Anxiety disorder caused by psychoactive substances 8. F42.- Obsessive-compulsive disorder (often accompanied by significant anxiety) 9. F48.8 Neurasthenia (may be accompanied by symptoms of anxiety and depression) 4. When using scale results (any of the following scales can be used, or other measurable scores/results suggestive of depression/anxiety tendencies): 1. Depressive state * Depression Self-Rating Scale (SDS) standard score ≥ 53 points, or suggesting depressive tendencies * Hamilton Depression Rating Scale (HAMD-17) ≥7 points, suggesting the presence of depressive symptoms * Patient Health Questionnaire-9 (PHQ-9) ≥ 5 points, suggesting the presence of depressive symptoms. 2. Anxiety state * Anxiety Self-Rating Scale (SAS) standard score ≥ 50 points, or suggesting anxiety tendencies * Hamilton Anxiety Scale (HAMA) ≥ 7 points, suggesting the presence of anxiety symptoms * Generalized Anxiety Disorder Scale (GAD-7) ≥ 5 points, suggesting the presence of anxiety symptoms. Exclusion criteria: 1. Serious cardiovascular, cerebrovascular, liver, kidney and other serious life-threatening primary diseases 2. Poorly controlled diabetes 3. There is a risk of suicide 4. Those with head trauma, loss of consciousness or severe mental disorders 5. Drug, drug or alcohol abusers 6. Received modified electrical convulsions (MECT/ECT), repetitive transcranial magnetic stimulation (r-TMS), vagus electrical stimulation (VNS), within half a year. 7. Those who have received antidepressant or psychotic drugs within half a year; 8. Those with severe skin injuries and skin diseases. 9. Self-injury or even suicidal behavior occurs during the research process; 10. Other diseases that suddenly become unsuitable for continued participation in the study during the study; 11. Other conditions that the supervising physician deems unsuitable for continued participation in the study.

Inclusion Criteria: Applicable to both groups : 1. Age ≥ 18 years 2. Eligible to undergo MRI examination 3. Prior clinical evaluation completed 4. Covered by a national health insurance scheme or beneficiary thereof (excluding State Medical Aid AME) 5. Patient informed and written informed consent obtained Specific to the MASLD group : 6. Indication for TIPS validated during a multidisciplinary team meeting and documented in the patient's medical record, including one of the following: * Refractory ascites * Hepatic hydrothorax * Failure of secondary prophylaxis of variceal gastrointestinal bleeding * Preemptive TIPS * Preoperative TIPS Specific to the MASLD group : 7. Past or current exposure to metabolic risk factors (overweight, obesity, type 2 diabetes mellitus, arterial hypertension, dyslipidemia) 8. Liver stiffness \> 15 kPa measured by transient elastography 9. Liver biopsy documenting steatosis with stage 3 fibrosis or cirrhosis 10. Alcohol consumption \< 20 g/day for women and \< 30 g/day for men, assessed using validated routine clinical questionnaires Exclusion Criteria: Applicable to both groups : 1. Any contraindication to MRI (cardiac pacemaker, implantable cardioverter-defibrillator, cochlear implants, intraocular metallic foreign bodies, intracranial vascular clips). 2. Prior liver transplantation. 3. Pregnancy, breastfeeding, or women of childbearing potential not using effective contraception. 4. Individual under legal guardianship or trusteeship, or unable to provide informed consent. 5. Participation in another interventional clinical study or currently within the exclusion period following a previous ongoing study. Specific to the TIPS group 6. Patients undergoing salvage TIPS placement in the setting of hemorrhagic shock. Specific to the MASLD group 7. Other etiologies of chronic liver disease, including viral hepatitis, autoimmune liver disease, or hemochromatosis

Inclusion Criteria: 1. Female patients aged ≥18 years. 2. Pathological diagnosis of invasive breast cancer or ductal carcinoma in situ. 3. Undergone breast-conserving surgery or total mastectomy, with or without stage I breast reconstruction. 4. For invasive carcinoma, sentinel lymph node biopsy, axillary lymph node sampling, or axillary lymph node dissection was performed. 5. Required postoperative adjuvant radiotherapy. 6. Karnofsky Performance Status (KPS) score ≥ 70. 7. The estimated life expectancy of greater than 5 years . 8. Planned to receive photon intensity-modulated radiotherapy (IMRT) or proton IMRT, with written informed consent obtained. Exclusion Criteria: 1. Prior history of chest radiotherapy. 2. Severe cardiopulmonary dysfunction or other conditions that contraindicate radiotherapy. 3. Pregnancy or breastfeeding. 4. Concurrent active malignancies.

Inclusion Criteria: All participants must meet the following criteria: 1. Written and voluntarily given Informed Consent. 2. Male or female ≥18 years of age at time of consent. 3. Have the capacity to understand the study and be willing and able to comply with all protocol requirements. 4. Participants with histologically confirmed or suspected tumors of the following types, but not limited to: Clear Cell Renal Cell Cancer; Urothelial Carcinoma; Colorectal Cancer; Cervical Cancer; Ovarian Cancer; Head and Neck Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Non Small Cell Lung Cancer; Small Cell Lung Cancer; Breast Cancer; Pancreatic Cancer; Endometrial Cancer; Von Hippel Lindau Disease. Exclusion Criteria: Participants will be excluded from participation in the study if one or more of the following criteria are met: 1. Have any serious non-malignant disease (e.g., psychiatric, infectious, autoimmune or metabolic) that may interfere with the objectives of the study or with the safety or compliance of the participant, as judged by the Investigator. 2. Have a mental impairment that may compromise the ability to give Informed Consent and comply with the requirements of the study. 3. Be a female who is pregnant or breastfeeding.

Inclusion Criteria: * Female patients aged 18 to 65 years * Diagnosed with breast cancer * Scheduled for elective mastectomy under general anesthesia * American Society of Anesthesiologists (ASA) physical status I-III * Able to understand and provide written informed consent * Body mass index (BMI) 18-29 kg/m² Exclusion Criteria: * Contraindications to regional anesthesia * Contraindications or allergy to ropivacaine or local anesthetics * Inability to use a visual analog scale (VAS) for pain assessment * Inability to understand or operate patient-controlled analgesia (PCA) * History of chronic pain or ongoing infection requiring treatment * History of chronic analgesic use * History of autoimmune disease * Uncontrolled systemic disease

Inclusion Criteria: 1\. At least one of the following clinical criteria (1 or 2) must be fulfilled: 1. Graft dysfunction, defined by at least one of the following: * Acute reduction in estimated glomerular filtration rate (eGFR) \>15% on two consecutive measurements at least 2 weeks apart, with other causes excluded (rejection, obstruction, infection). * eGFR \<50% of the expected value 30 days after kidney transplantation of unknown cause. * Decline in eGFR \>30% after initiation of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. 2. Persistent resistant hypertension for more than 6 weeks after kidney transplantation, defined as: * 24-hour ambulatory systolic blood pressure \>130 mmHg despite treatment with at least three classes of antihypertensive medication at maximally tolerated doses (including diuretics, if tolerated). Together with at least one of the following radiological criteria: 1. CT or MR angiography demonstrating a lumen reduction ≥50%. 2. Doppler ultrasound showing: 1. Peak systolic velocity in the renal artery ≥200 cm/s and a renal renal ratio (velocity at stenosis / velocity in distal artery) \>4. 2. Acceleration time \>70 ms in intrarenal arteries. 2\. In cases of strong clinical suspicion of a vascular complication where CT or MR angiography cannot reliably exclude graft artery or vein stenosis, patients may be referred for confirmatory invasive investigations. Before PTA, catheter-based angiography and translesional pressure measurements are performed to confirm whether the patient meets the radiological eligibility criterion for PTA: 1. Stenosis ≥70%. 2. Stenosis 50-69% if at least one of the following criteria is met: * Mean translesional pressure gradient ≥10 mmHg. * Systolic pressure gradient ≥20 mmHg. * Renal Pd/Pa ≤0.8. * If pressure measurements cannot be obtained, treatment is based on the operator's clinical judgement. Exclusion Criteria: 1. Inability to provide informed consent. 2. Concurrent biopsy demonstrating rejection requiring treatment. 3. Pregnancy. 4. Previous PTA of the same vessel. 5. Patients unable to tolerate any form of antithrombotic therapy and therefore not eligible for stent placement.

Inclusion Criteria: 1. Patients aged 18 to 75 years. 2. Patients have been diagnosed with metastatic HER2 negative breast cancer. HER2 status were determined locally by immunohistochemistry (IHC) of patients' primary or metastatic tumor sections. HER2-negative status was defined by IHC staining 0 to 1+ or fluorescence in situ hybridization ratio \<2.0 if IHC 2+ or IHC not performed. 3. The metastatic disease was confirmed by clinical, imaging, histological, or cytological measures, including unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer. 4. ECOG-PS ≤2 5. For patients with triple-negative breast cancer (TNBC): at least 1 line of systemic therapy in the metastatic setting; for patients with HR+/HER2- breast cancer: prior treatment with endocrine therapy and CDK4/6 inhibitors, and at least 1 line of systemic therapy in the metastatic setting. 6. At least one evaluable lesion by CT or MRI according to RECIST 1.1. 7. Willing to accept the treatment by the investigator based on the patient's preference, physical condition, prior treatment history, and financial circumstances. 8. Willing to use contraceptive measures during the study period. 9. Willing and able to complete electronic questionnaires/scales on a smartphone, tablet, or other electronic device. 10. All patients can provide an informed consent before enrolment and data collection. Exclusion Criteria: 1. Insufficient bone marrow, hepatic, or renal function, defined as: * Bone marrow: White blood cell count \< 3.0 × 10⁹/L, or absolute neutrophil count \< 1.5 × 10⁹/L, or platelet count \< 75 × 10⁹/L, or hemoglobin \< 8.0 g/dL. * Hepatic function: Total bilirubin \> 1.5 × upper limit of normal (ULN), or ALT/AST \> 3.0 × ULN (or \> 5.0 × ULN in the presence of liver metastases). * Renal function: Serum creatinine \> 1.5 × ULN, or creatinine clearance \< 50 mL/min. 2. History of other malignancies or hematologic malignancies. 3. Hypersensitivity to the study treatment drugs. 4. Systemic anti-tumor therapy (including chemotherapy, radiotherapy, immunotherapy, etc.) within 2 weeks prior to study drug administration. 5. Treatment with an investigational product within 4 weeks before the first treatment. 6. Presence of any toxicity from prior therapy (excluding alopecia) ≥ Grade 2 according to CTCAE version 5.0, prior to study drug administration. 7. Systemic inflammatory diseases, including but not limited to systemic lupus erythematosus, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, or active vasculitis. 8. Severe psychiatric or neurological disorders, including but not limited to schizophrenia, depression, mania, Alzheimer's disease, myasthenia gravis, seizure disorders, or known conditions that may provoke seizures. 9. Pregnant or breastfeeding women.

Inclusion Criteria: * Female patients aged ≥18 years * Histologically confirmed breast cancer * Ongoing treatment with CDK 4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib) * Ability to understand and provide informed consent * Access to a telephone or digital communication device for telenursing follow-up Exclusion Criteria: * Inability to comply with the study procedures * Cognitive impairment or psychiatric conditions interfering with participation * Participation in another interventional clinical trial that may affect study outcomes * Severe comorbidities limiting life expectancy or follow-up